Macquarie Group’s Theriva Biologics TOVX Stock Holding History

Macquarie Group’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2	Closed	-$8K	–	2357
2017 Q4	$8K	Buy	+2	New	+$12.5K	﹤0.01%	2311

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Macquarie Group's TOVX Position: Q1 2018 in Review

Macquarie Group sold out of Theriva Biologics (TOVX) in Q1 2018, closing a stake of 2 shares — an estimated $8K sold.

Macquarie Group first reported a position in TOVX in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 48 funds tracked by Wall St. Rank hold TOVX as of Q1 2018.

Macquarie Group reported no remaining Theriva Biologics position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 2 Theriva Biologics shares in Q1 2018, an estimated $8K.
Macquarie Group first reported a position in Theriva Biologics in Q4 2017 and held it in 1 quarter.
Macquarie Group's Theriva Biologics position peaked at $8K in Q4 2017.
48 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.